Little is known about the psychological burden patients are left with after successful allogeneic hematopoietic SCT (HSCT). With the main focus on physical condition and common transplant complications, psychological symptoms often remain neglected in daily practice. To assess the prevalence of distress in patients who have undergone allogeneic HSCT, we conducted a cross-sectional pilot study in 50 consecutive patients from our outpatient transplant clinic using standardized questionnaires. Distress was categorized by symptoms of anxiety, fear of progression, depression and post-traumatic stress disorder (PTSD). Forty-one patients completed self-administered questionnaires. The median age was 53 years (21-74 years) and the mean time after transplantation was 614 days (25-2070 days). In total, 18 patients (44%) showed symptoms of distress. Among these 18 patients, 11 patients reported symptoms of anxiety, 12 patients suffered from fear of progression, 11 patients showed symptoms of depression and 6 patients of PTSD. Age below 55 years was significantly associated with fear of progression (P ¼ 0.004). This study demonstrates the high prevalence of distress in patients who have undergone allogeneic HSCT. Our results suggest an unmet need for professional support and intervention. These findings may be relevant as distress could have an influence on the outcome after HSCT.
INTRODUCTION
Allogeneic hematopoietic SCT (HSCT) is often the only curative treatment option in patients with various hematological and lymphatic malignancies. 1, 2 The unique graft-versus-malignancy effect promises a cure when other treatment options such as intensified chemotherapy or auto-SCT have failed. 3 Nevertheless, even though allogeneic HSCT promises to cure an otherwise terminal disease, this option is associated with significant risks and burdens such as life-threatening GvHD and infectious complications. Intensive research and accumulating clinical experience have significantly improved the overall worldwide competence in this field. 4, 5 Nowadays allogeneic HSCT can be regarded as a standard of care treatment with a reasonable rate of TRM. [6] [7] [8] Ongoing research largely focuses on strategies to further improve patient safety and the rate of cure of the underlying malignant disease. This single-minded focus on further reduction of TRM and relapse often neglects the potential impact of psychological distress on the patient. 9, 10 The National Comprehensive Cancer Network assumes that o10% of patients with oncological disorders receive adequate psycho-oncological support. 11, 12 Although investigations of psychological distress are being studied in the field of solid tumor oncology, only limited experience in patients undergoing HSCT is available so far. In the context of HSCT, the focus has clearly been on auto-HSCT. In these investigations, up to 40% of the patients experienced high levels of distress; stress being defined with symptoms of anxiety or depressive disorder, while up to 19% of patients suffered from potential post-traumatic stress disorder (PTSD). [13] [14] [15] [16] [17] [18] [19] [20] In summary, these studies show that psychological distress is frequent, often associated with additional somatic and demographic variables such as GvHD, age gender or marital status and improved over time, albeit slowly. 13 Unfortunately, often it remains uncertain whether patients identified with psychological distress received appropriate treatment so that very little is known about the effects of professional intervention or support. In the current study, we present the results of a cross-sectional analysis performed in patients having undergone allogeneic HSCT focusing on anxiety, depressive disorder, PTSD and professional psychiatric care while considering transplant-specific covariables.
SUBJECTS AND METHODS

Study design and patients
This study was planned as a cross-sectional analysis of a minimum of 25 assessable patients who had undergone allogeneic HSCT in the Allogeneic Stem Cell Transplant Center of the University of Wü rzburg and were receiving their post-transplant care at the local outpatient center. To compensate for non-completed or non-returned questionnaires, double the number of patients could be enrolled. It was the aim of this descriptive study to assess the frequency of psychiatric disorders and respective treatment. Standardized questionnaires were used as diagnostic measures and to obtain sociodemographic variables. Clinical data were obtained from the records. In this context, all patients were offered psychooncological support by professional staff in the outpatient setting. The study was approved by the local ethics committee. Patients were able to participate in this trial after providing written informed consent.
Assessment of symptoms of distress
The Generalized Anxiety Disorder 7-item (GAD-7) scale, 21, 22 Fear of Progression Questionnaire-Short Form (FoP-Q-SF), 23, 24 Patient Health Questionnaire 9-item (PHQ-9), [25] [26] [27] and the 17-item PTSD ChecklistCivilian Version (PCL-C) [28] [29] [30] were used as instruments to assess anxiety, depression and PTSD. All instruments were previously validated accordingly and showed a high reliability (internal consistency above 0.85). Patients were considered distressed when they had scores X10 on the GAD-7, or X10 on the PHQ-9, or X34 on the FoP-Q-SF, or a PCL-C total score X50. By using these cutoffs, 'normal' or 'mild' forms of anxiety and depression were excluded from the study, focusing solely on 'moderate' and 'severe' presentations and thereby allowing to focus on clinically relevant findings. 21, 27 Clinical and sociodemographic data Clinical data including the psychiatric or psychotherapeutic history were obtained from the patients' records. Sociodemographic data including age, gender and marital status were obtained using an established questionnaire. 31 
Statistical analysis
In this cross-sectional study, sample characteristics are presented as percentages, means and standard deviations. Comparisons between distressed and non-distressed patients were carried out using the Fisher's exact test for categorical variables. To compare means in two groups, the unpaired t-test and the Mann-Whitney U-test were used where indicated. A P-value o0.05 was considered statistically significant. The statistical analyses were conducted using the IBM SPSS statistics software version 19 (SPSS Inc., Chicago, IL, USA). Patients above the age of 55 years were defined as elderly patients.
RESULTS
Participants
Between July and August 2011, 50 eligible patients were consecutively invited to participate in this study. All patients provided informed consent in writing. A total of 41 (82%) patients were assessable for final analysis. Nine patients failed to complete or return the questionnaire and were therefore excluded from the analysis (18%). Mean age in the 41 patients assessable for analysis was 53 years (ranging from 21 to 74 years). The mean time after allogeneic HSCT was 614 days (range: 25-2070 days) at the day of assessment. The patients' characteristics are detailed in Table 1 .
Distress
Of the 41 patients assessable for analysis, 11 (27%) had moderate or severe symptoms of anxiety. Significant symptoms of depression were present in 11 (27%) patients. Fear of progression was documented in 12 (29%) patients, whereas 6 (15%) patients had significant symptoms of PTSD. Taken together, a total of 18 (44%) patients were distressed in at least one category (details are shown in Table 2 ). Younger patients reported significantly more fear of progression (P ¼ 0.004). There were no significant results concerning other sociodemographic variables (Table 3) . Furthermore, there were no significant associations between CMV reactivation, acute or chronic GvHD, time after ASCT and distress (Table 4) .
Psychiatric care
Out of 18 patients with distress, only 7 (39%) received psychopharmacological treatment, including antidepressant and/ or anxiolytic drugs. Only four (22%) of these 18 patients received professional psychotherapy. Out of 23 patients without distress, one received psychopharmacological treatment.
DISCUSSION
We decided to study the prevalence of distress and the rate of professional support in patients who had undergone allogeneic HSCT for various reasons. Results from Lee and co-workers 16 obtained in a group of patients who mainly underwent autologous transplantation showed 44% of the patients to be distressed. We could confirm this rate of prevalence in our group of patients having undergone solely allogeneic HSCT with an equal prevalence of 44%. Results obtained from studies in patients with various malignancies suggest lower rates of distress in patients with solid tumors. 32, 33 Regarding the subgroups of psychological distress such as anxiety, depression and PTSD, results from our study were very similar to those reported by Lee et al. 16 in the mixed autologous and allogeneic setting (27% versus 33%, 27% versus 27% and 15% versus 11%, respectively). 16 This suggests that allogeneic and autologous HSCT results in a similar rate and quality of distress. Taking the significantly higher Type of allo-HSCT Matched related donor, n (%) 9 (22%) Matched unrelated donor, n (%) 21 (51%) Mismatch, haploidentical, cord blood, n (%) 11 (27%)
Selected complications Acute GvHD II-IV (overall), n (%) 9 (22%) Chronic GvHD (limited and extensive), n Distress after allogeneic HSCT J Hefner et al transplant-associated mortality of allogeneic HSCT in comparison to autologous HSCT into account, this is a rather unexpected finding. Patients' perception of danger and fear may be irrational and therefore does not always correlate with the rate of expected severe complications in an objective manner. This highlights the urgent need for standardized psycho-oncological screening and individual support procedures in the transplant setting. Recently published work in patients having undergone various forms of HSCT suggests that regular self-assessment of distress using the PHQ questionnaire is able to provide efficiently a comprehensive and timely briefing to the treating physician who is then more likely to address these issues adequately. 34 We did not see significant effects of acute or chronic GvHD, CMV reactivation or time after allogeneic SCT on the levels of distress. The latter finding was rather unexpected as other studies suggested the level of distress to decline over time following transplantation. 13 In contrast to our findings Sun and co-workers 35 described a twofold increase in somatic distress levels in patients with active chronic GvHD as compared with a group of healthy siblings in more than thousand long-term survivors of HSCT. Our group of consecutively interviewed patients was rather heterogeneous with respect to the underlying diseases and stages and standard transplant variables. A larger trial in a more homogeneous group of patients may therefore have provided different findings. It has been proposed by Jim et al. 12 and Mosher et al. 13 to include cancer-specific core qualities of anxiety such as fear of progression into psycho-oncological studies. We have addressed this need by using an established questionnaire that also includes fear of progression. Almost every third of our patients (29%) suffered from fear of progression, which is a novel finding that to our knowledge has not been reported before in patients undergoing allogeneic HSCT. In our study, younger patients had a significantly higher rate of fear of progression, suggesting that these patients require our attention and close psychological guidance. This finding is of particular relevance with regard to treatment options as different qualities of distress may require different interventions. Reducing therapeutic efforts to a general and broadly applicable medication is therefore unlikely to be successful. As a consequence, psychological support and therapy for patients undergoing allogeneic HSCT should be as individualized as in somatic therapy. Unfortunately, the rate of psychological support in our study was extremely low. Only 7 of 18 distressed patients received support, whereas 3 were treated solely with psychopharmacological medication reflecting an insufficient level of support in our patients. Lee et al. 16 reported Distress after allogeneic HSCT J Hefner et al a higher rate of professional support that may reflect geographical differences in standardized care. This study was performed in the allogeneic setting and revealed a significant amount of distress where almost every second patient showed symptoms of anxiety, depression or PTSD. These preliminary results of a single-center cross-sectional study in a rather heterogeneous group of patients reflect a high demand for professional psycho-oncological support. Comprehensive psycho-oncological support should commence before performing the transplant procedure and may not only improve patients' quality of life but may also have an influence on the outcome after HSCT, as suggested by several trials. [36] [37] [38] [39] [40] 
